Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data

Aldeyra Therapeutics isn’t giving up on its drug candidate for dry eye disease despite a challenging path so far. The company is preparing to file reproxalap with the FDA for the third time after a ...